482
Views
4
CrossRef citations to date
0
Altmetric
Original Article

Carbocyclic potential DNA minor groove binders and their biological evaluation

, &
Pages 629-634 | Received 16 Jul 2009, Accepted 06 Oct 2009, Published online: 30 Apr 2010

References

  • Nelson SM, Ferguson LR, Denny WA. Non-covalent ligand/DNA interactions: minor groove binding agents. Mutat Res 2007;623:24–40.
  • Neidle S. DNA minor-groove recognition by small molecules. Nat Prod Rep 2001;18:291–309.
  • Baraldi PG, Bovero A, Fruttarolo F, Preti D, Tabrizi MA, Pavani MG, et al. DNA minor groove binders as potential antitumor and antimicrobial agents. Med Res Rev 2004;24:475–528.
  • Bailly C. Sequence-specific recognition and modification of double-helical DNA by minor-groove binding conjugates structurally related to netropsin and distamycin. In: Palumbo M, ed. Advances in DNA Sequence-Specific Agents. London: JAI Press, 1998;3:97-156.
  • Kopka ML, Yoon C, Goodsell D, Pjura P, Dickerson RE. The molecular origin of DNA-drug specificity of netropsin and distamycin. Proc Natl Acad Sci USA 1985;82:1376–80.
  • Pindur U, Jansen M, Lemster T. Advances in DNA-ligands with groove binding, intercalating and/or alkylating activity: chemistry, DNA-binding and biology. Curr Med Chem 2005;12:2805–47.
  • Bartulewicz D, Markowska A, Wołczyński S, Dąbrowska M, Różański A. Molecular modelling, synthesis and antitumour activity of carbocyclic analogues of netropsin and distamycin – new carriers of alkylating elements. Acta Biochim Polon 2000;47:23–35.
  • Bartulewicz D, Bielawski K, Bielawska A, Różański A. Synthesis, molecular modelling, and antiproliferative and cytotoxic effects of carbocyclic derivatives of distamycin with chlorambucil moiety. Eur J Med Chem 2001;36:461–7.
  • Bielawski K, Bielawska A, Bartulewicz D, Różański A. Molecular modelling of the interaction of carbocyclic analogues of netropsin and distamycin with d(CGCGAATTCGCG)2. Acta Biochim Polon 2000;47:855–66.
  • Drozdowska D, Rusak M, Miltyk W, Midura-Nowaczek K. Synthesis and biological evaluation of distamycin analogues - new potential anticancer agents. Arch Pharm Chem Life Sci 2009;342:87-93.
  • Bartulewicz D, Anchim T, Midura-Nowaczek K. Synthesis and cytotoxic effect of carbocyclic potential minor groove binders. Farmaco 2004;59:211–14.
  • Morgan AR, Lee JS, Pulleyblank DE, Murray NL, Evans DH. Ethidium fluorescence assays 1. Physiochemical studies. Nucleic Acids Res 1979;7:547–69.
  • Debart F, Periguad C, Gosselin D, Mrani D, Rayner B, Le Ber P, et al. Synthesis, DNA binding, and biological evaluation of synthetic precursors and novel analogues of netropsin. J Med Chem 1989;32:1074–83.
  • Schmitt M, Wilhelm OG, Reuning U, Krüger A, Harbeck N, Lengyel E, et al. The urokinase plasminogen activator system as a novel target for tumour therapy. Fibrinolysis Proteolysis 2000;14:114–32.
  • Andreasen PA, Kjoller L, Christensen J, Duffy MJ. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 1997;72:1–22.
  • Pućkowska A, Midura-Nowaczek K, Bruzgo I. Effects of netropsin and pentamidine amino analogues on the amidolytic activity of plasmin, trypsin and urokinase. Acta Polon Pharm 2008;65:213-215.
  • Okada Y, Tsuda Y, Teno N, Wanaka K, Bohgaki M, Hijikata-Okunomiya A, et al. Synthesis of active center-directed peptide inhibitors of plasmin. Chem Pharm Bull 1988;36:1289–97.
  • Tamura S, Weinhouse MI, Roberts CA, Goldman EA, Masukawa K, Anderson SM, et al. Synthesis and biological activity of peptidyl aldehyde urokinase inhibitors. Biorg Med Chem Lett 2000;10:983–7.
  • Lown JW. Newer approaches to the study of the mechanisms of action of antitumor antibiotics. Acc Chem Res 1982;15:381–7.
  • Bartulewicz D, Bielawski K, Bielawska A. Carbocyclic analogues of netropsin and distamycin: DNA-binding properties and inhibition of DNA topoisomerases. Arch Pharm Pharm Med Chem 2002;9:422–6.
  • Capranico G, Borginetto ME, Cornarotti M, Zagni E, Palumbo M, Zunino F Sequence-specific poisons of type II DNA topoisomerases. In: Palumbo M, ed. Advances in DNA Sequence-Specific Agents. London: JAI Press, 1998;3:7–38.
  • Gatto B, Fong Liu L. Topoisomerase I-targeting drugs: new developments in cancer pharmacology. In: Palumbo M, ed. Advances in DNA Sequence-Specific Agents. London: JAI Press, 1998;3:39–66.
  • Champoux JJ. DNA topoisomerases: structure, function, and mechanism. Annu Rev Biochem 2001;70:369–413.
  • Dass K, Ahmad A, Azmi AS, Sarkar SH, Sarkar FH. Evolving role of uPA/uPAR system in human cancers. Cancer Treat Rev 2008;34:122–36.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.